News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,762 Results
Type
Article (45798)
Company Profile (341)
Press Release (662623)
Section
Business (208759)
Career Advice (2219)
Deals (36239)
Drug Delivery (101)
Drug Development (82405)
Employer Resources (173)
FDA (16251)
Job Trends (15201)
News (352383)
Policy (33140)
Tag
Academia (2571)
Alliances (50732)
Alzheimer's disease (1284)
Approvals (16210)
Artificial intelligence (153)
Bankruptcy (363)
Best Places to Work (11681)
Biotechnology (248)
Breast cancer (192)
Cancer (1409)
Cardiovascular disease (115)
Career advice (1839)
CAR-T (105)
Cell therapy (305)
Clinical research (65867)
Collaboration (510)
Compensation (264)
COVID-19 (2591)
C-suite (118)
Data (1412)
Diabetes (178)
Diagnostics (6240)
Earnings (85774)
Employer resources (152)
Events (113807)
Executive appointments (409)
FDA (16957)
Funding (452)
Gene therapy (211)
GLP-1 (629)
Government (4381)
Healthcare (18836)
Infectious disease (2687)
Inflammatory bowel disease (119)
Interviews (352)
IPO (16665)
Job creations (3925)
Job search strategy (1585)
Layoffs (433)
Legal (8067)
Lung cancer (201)
Manufacturing (221)
Medical device (13266)
Medtech (13271)
Mergers & acquisitions (19747)
Metabolic disorders (480)
Neuroscience (1623)
NextGen Class of 2024 (6660)
Non-profit (4514)
Northern California (1732)
Obesity (271)
Opinion (226)
Patents (125)
People (58156)
Phase I (20593)
Phase II (29063)
Phase III (21527)
Pipeline (527)
Postmarket research (2584)
Preclinical (8740)
Radiopharmaceuticals (239)
Rare diseases (279)
Real estate (6247)
Regulatory (22163)
Research institute (2365)
Resumes & cover letters (376)
Southern California (1492)
Startups (3817)
United States (15602)
Vaccines (592)
Weight loss (197)
Date
Today (34)
Last 7 days (99)
Last 30 days (2118)
Last 365 days (36013)
2024 (36013)
2023 (40712)
2022 (51900)
2021 (56373)
2020 (54695)
2019 (47169)
2018 (35606)
2017 (33143)
2016 (32596)
2015 (38470)
2014 (33847)
2013 (28963)
2012 (29451)
2011 (30123)
2010 (28199)
Location
Africa (796)
Arizona (199)
Asia (39299)
Australia (6596)
California (3914)
Canada (1469)
China (321)
Colorado (175)
Connecticut (183)
Europe (85419)
Florida (542)
Georgia (136)
Illinois (415)
Indiana (231)
Maryland (651)
Massachusetts (3049)
Michigan (176)
Minnesota (305)
New Jersey (1138)
New York (1106)
North Carolina (777)
Northern California (1732)
Ohio (147)
Pennsylvania (944)
South America (1186)
Southern California (1492)
Texas (566)
Utah (111)
Washington State (407)
708,762 Results for "kane biotech inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to Progena
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”).
June 27, 2024
·
4 min read
Business
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.First Commercial Agreement for DispersinB®
Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.
June 25, 2024
·
3 min read
Business
Kane Biotech Announces First Quarter 2024 Financial Results
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results.
May 23, 2024
·
8 min read
Press Releases
Kane Biotech Announces Third Quarter 2024 Financial Results
November 29, 2024
·
10 min read
Press Releases
Kane Biotech Announces $3,000,000 Private Placement Offering
December 3, 2024
·
3 min read
Kane Biotech to Host Investor Webinar
Kane Biotech Inc. announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.
April 16, 2024
·
2 min read
Press Releases
Kane Biotech Announces Agreement to Acquire FB Dermatology
November 12, 2024
·
8 min read
Business
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
Kane Biotech Inc. will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024.
May 16, 2024
·
2 min read
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
Kane Biotech Inc. announces its intent to commercialize the patented assay which is to be named the Schultz Biofilm Wound Map in honour of the late Dr. Greg Schultz, former Professor Emeritus at the University of Florida and Chief Science Officer of Kane.
May 15, 2024
·
4 min read
Press Releases
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
November 28, 2024
·
5 min read
1 of 70,877
Next
